# EDGAR Filing Document

**Accession Number:** 0001098009
**File Stem:** 0001185185-25-001200
**Filing Date:** 2025-9
**Character Count:** 4764
**Document Hash:** c44102b2f23a6dc919b360a8f0c0bea3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-25-001200.hdr.sgml**: 20250915

**ACCESSION NUMBER**: 0001185185-25-001200

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20241004

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20250915

**DATE AS OF CHANGE**: 20250912

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** America Great Health
- **CENTRAL INDEX KEY:** 0001098009
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980178621
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-27873
- **FILM NUMBER:** 251313048

**BUSINESS ADDRESS:**
- **STREET 1:** 1609 W VALLEY BLVD UNIT 338A
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91803
- **BUSINESS PHONE:** (888) 988-1333

**MAIL ADDRESS:**
- **STREET 1:** 1609 W VALLEY BLVD UNIT 338A
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CROWN MARKETING
- **DATE OF NAME CHANGE:** 20111006

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPACE LAUNCHES FINANCING INC
- **DATE OF NAME CHANGE:** 19991028

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 04, 2024

**<u>America Great Health</u>**

(Exact name of registrant as specified in charter)

**<u>wyoming</u>**

(State or other jurisdiction of incorporation)

---

| | |
|:---|:---|
| **0-27873** | **98-0178621** |
| (Commission File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **1609 W Valley Blvd., #338,<br> Alhambra, CA 91803** | **28277** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(626) 576-1299**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |

---

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

On June 2nd, 2025, the Company accepted the resignation of Quinn Chen as Chief Financial Officer of the Company to be effective June 30, 2025. Mr. Chen is resigning for personal reasons and there were no disagreements between him and the Company. His departure is not related to the operations, policies or practices of the Company or any issues regarding accounting policies or practices.

The Board of Directors of the Company intends to conduct a search of potential internal and external candidates to replace Mr. Chen. In the interim, the Company's President and Chief Executive Officer, Mike Wang, will serve as the Chief Financial Officer, to assume the duties as principal financial officer and principal accounting officer of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AMERICA GREAT HEALTH** | **AMERICA GREAT HEALTH** |
| Date: September 12, 2025 | By: | /s/ Mike Q. Wang |
|  | Name: | Mike Q. Wang |
|  | Title: | President/CFO |

---